Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Proton Therapy
83%
Chemoradiotherapy
57%
Lung Cancer
57%
Radiation Therapy
38%
Neoplasm
33%
Intensity Modulated Radiation Therapy
26%
Radiation Pneumonia
21%
Durvalumab
18%
Volume CT
16%
Thorax Tumor
16%
Overall Survival
15%
Contouring
15%
Immunotherapy
15%
Small Cell Lung Cancer
15%
Non-Small Cell Lung Cancer
15%
Breathing
14%
Stereotactic Body Radiation Therapy
14%
Photon Therapy
14%
Volumetric Modulated Arc Therapy
13%
Conformal Radiotherapy
13%
Image Quality
13%
Positron Emission Tomography
13%
Primary Tumor
13%
Dose Calculation
13%
Acute Toxicity
11%
Lung Tumor
10%
Cone Beam Computed Tomography
9%
Odds Ratio
9%
Stereotactic Radiotherapy
9%
Radiation Therapy Planning
9%
Fluorodeoxyglucose F 18
9%
Radiation Oncology
8%
Dose-Volume Histogram
8%
Head and Neck Tumor
7%
Continuous Positive Airway Pressure
7%
Tumor Metabolism
7%
Bilevel Positive Airway Pressure
7%
Positron Emission Tomography
7%
Hypoxia
7%
Proteus
7%
Atrium (Heart)
7%
Breast Cancer
7%
Computer Assisted Tomography
7%
Ventricle (Heart)
7%
Pneumonia
7%
Cardiovascular System
7%
Ticilimumab
7%
Survival Prediction
7%
Heart Left Ventricle Failure
7%
Keyphrases
Non-small Cell Lung Cancer Patients
39%
Lung Cancer
23%
4D Dose Accumulation
20%
Non-small Cell Lung Cancer (NSCLC)
18%
Chemoradiotherapy
18%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
16%
Normal Tissue Complication Probability
15%
Multivariable
15%
Intensity-modulated
15%
Acute Toxicity
15%
Normal Tissue Complication Probability Models
13%
4D Dose Reconstruction
13%
Esophageal Toxicity
12%
Radiotherapy
12%
Stereotactic Body Radiotherapy
11%
Deep Learning
9%
Stereotactic Radiotherapy
9%
Organs at Risk
9%
Cancer Audit
8%
Dutch
8%
Interface Test
7%
Immune Checkpoint Inhibitors
7%
Non-responders
7%
CD8+ T Cell Infiltration
7%
Normal Tissue Complications
7%
4DCT
7%
Radiation Dose
7%
Stage I-IIIA
7%
Assessment Method
7%
Intrafraction
7%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
7%
3-month Mortality
7%
Image Features
7%
Dose-surface Maps
7%
Reader Study
7%
Radiotherapy Boost
7%
Early Response Monitoring
7%
Netherlands
7%
Large-scale Motions
7%
Non-gated
7%
Proton Dose
7%
Cardiac Atria
7%
Survival Prediction
7%
Interfractional
7%
Continuous Beam
7%
Chemoradiation
7%
Small Cell Lung Cancer
7%
Respiratory Gating
7%
90-day Mortality
7%
Target Volume Delineation
7%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
93%
Chemoradiation Therapy
63%
Lung Cancer
48%
Malignant Neoplasm
24%
Overall Survival
17%
Radiation Pneumonia
16%
Primary Tumor
15%
Acute Toxicity
11%
Cisplatin
10%
Neoplasm
10%
Immunotherapy
9%
Chemotherapy
9%
Cancer Staging
7%
Brain Metastasis
7%
Thorax Tumor
7%
Durvalumab
7%
Pneumonia
7%
Survival Prediction
7%
Tolerability
7%
Hodgkin Disease
7%
Chemotherapy Regimens
7%
Tremelimumab
7%
Heart Left Ventricle Failure
7%
Lung Toxicity
6%
Dose-Volume Histogram
5%
Clinical Trial
5%
Deterioration
5%
